ClinicalTrials.gg
Not yet recruitingNCT07682168DIVIDEUpdated Jul 2, 2026

DIVision of the Interlobar Fissure in Patients Who Do Not Respond to Endobronchial Lung Volume Reduction

An interventional study of Surgical Lung Fissure Division in Chronic Obstructive Pulmonary Disease (COPD), Emphysema and Lung Volume Reduction Surgery, sponsored by Rocco Bilancia. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Rocco Bilancia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Surgical division of fissure is hypothesized to be safe and feasible. However, there is no preparatory study to test this hypothesis. It is logically expected that morbidity from the procedure could be less than standard LVRS and in preparation to a side-to-side trial of fissure division versus standard LVRS, a safety and feasibility study is required to test this hypothesis and inform future trial design.

Read the detailed description
  • Rationale

Lung volume reduction surgery (LVRS) and Endobronchial lung volume reduction (EBLVR) are both established treatment options for selected patients with symptomatic emphysema. In a randomized trial EBLVR was found to be non-inferior to LVRS in efficacy but uses fewer hospital resources.

Fissure completeness is however necessary for EBLVR to work and this is initially assessed on CT imaging and quantified by a software-based analysis called StratX. If anatomical completeness is less than 80% on StratX, EBLVR cannot be pursued, whereas if fissures are more than 80% complete, further functional assessment with a bronchoscopy and a balloon test called Chartis is required. The presence of a functionally incomplete fissure is called collateral ventilation and precludes EBLVR. If collateral ventilation is absent, EBVs can then be inserted in the target lung lobe.

The intended outcome of the procedure is the achievement of target lobar atelectasis (TLA), leading to reduced hyperinflation and improvement of the dyspnea.

When TLA is not achieved, current best practice is to obtain a CT to check for signs of EBV displacement or paravalvular leak. A further post-procedure StratX is also obtained to identify which valves or airways are affected. A revisional bronchoscopy is then performed to replace/reinsert valves or exclude other causes of malfunctioning such as mucus plugs or granulation tissue formation.

A proportion of patients (up to 20%) will however not show significant TLA despite optimisation or exclusion of EBV malfunctioning at revisional bronchoscopy. When this is the case, surgery in the form of LVRS is the only available treatment for this group of patients. Morbidity from this procedure though is significantly higher, requiring much longer recovery, hospitalization and use of healthcare resources.

The absence of TLA following EBLVR is commonly explained with the appearance of delayed /occult collateral ventilation through an anatomically incomplete fissure despite a favourable initial Chartis assessment..

We hypothesize that this limitation of EBLVR can be addressed by the elimination of collateral ventilation by surgical division of the incomplete interlobar fissure.

Partially complete fissures would also logically require a reduced extent of lung resection and a reduced number of stapled lines compared to LVRS; in addition, given the presence of the already implanted EBVs in the target lobe, this may potentially result in reduced postoperative air leak from resection of fragile lung tissue, hospital stay and complications.

Furthermore, this maneuver is already part of the repertoire of thoracic surgeons as it is required in most lung resection procedures (lobectomy, segmentectomy) for lung cancer.

Fissure division with endobronchial valves in-situ will also allow for intraoperative visual confirmation of target lobe collapse at the end of the procedure with increased chances of volume reduction benefit than can be assumed from EBLVR alone. Operative time may be less or equivalent to LVRS.

In this study, recruitment will be limited to non-responders EBLVR patients. Other causes for lack of response would be excluded prior to recruitment as per routine practice (CT analysis and revisional bronchoscopy). Based on current practice, an average of 3-5 patients per year per centre would be eligible. This safety and feasibility study is therefore designed to include at least 15 treated subjects from 4 UK centres over a period of 18 months. Or 18 months from each site opening to recruitment.

Data collected will inform further larger scale studies in LVR-naïve patients with proven incomplete fissures (concomitant EBV placement and fissure division) and a randomized controlled trial of surgical fissure division + EBV, against standard LVRS.

  • Intervention

Thoracoscopic (video assisted or robotic assisted) surgical division of interlobar fissure. Under GA, the patients will be positioned in lateral decubitus. Single lung ventilation. Standard thoracoscopic approach as per individual surgeon preference or practice. Fissure identified and surgical division with mechanical stapler performed.

  • Potential risk and benefits

The patients will have already undergone an extensive selection process for EBLVR and an unsuccessful initial EBLVR procedure without clinical benefit.

Having already excluded at revisional bronchoscopy (pre-enrollment in the trial) any malfunctioning or malpositioning of the valves, at the conclusion of the procedure, the intended outcome (target lobar collapse) has a very high probability of being achieved and can be directly visualized and confirmed during thoracoscopy. This may lead up to a 40% improvement in lung function and exercise ability with a consequent durable improvement in quality of life. Further hospital admissions may also be reduced.

We would logically expect morbidity and hospital stay to be less than LVRS, with shorter recovery time and increased chances of achieving the intended outcome. However to demonstrate this, a side-to-side trial of fissure division against standard LVRS would be required. This present study will build the foundations and help inform the design of said trial.

In this study, as the objective is to demonstrate the safety and feasibility of the trial procedure, we want to see and expect to see that morbidity is at least in line with, or less than what expected with standard LVRS, which would be the only other option available for this group of patients.

With standard LVRS, 30-day mortality risk would be up to 3-4%. The most common expected morbidity is protracted air leak requiring drainage with a hospital stay of up to 14 days. Other risks include severe chest infection/exacerbation leading most commonly to type 2 respiratory failure, acute and chronic chest pain, cardiovascular morbidity (DVT-PE, MI, stroke, arrhythmia, heart failure) as well as all other common generic risks related to surgery/general anaesthesia. Risk of conversion to thoracotomy is negligible.

Standard perioperative care will be used.

Currently, in the eligible patient population, the alternatives will therefore be to do nothing and accept ongoing poor condition, or standard LVRS with potential for greater air leak, hospital stay and higher risk of drain-related complications i.e. pain/infection. Rather than a novel procedure, the proposed trial procedure would be an alternative, lesser procedure for patients, utilizing a surgical approach (division of anatomical fissure) that is already in the standard and essential repertoire of thoracic surgeons, being performed by each surgeon in at least 50-100 anatomical lung resection per year.

  • Study Hypothesis

The study hypothesis states that it is safe to perform minimally invasive interlobar fissure division in patients who have not responded to prior EBLVR due to occult collateral ventilation. We also hypothesize that it is feasible to recruit the intended number of patients and that complete fissure division, which is the prerequisite to obtain the required target lobe collapse, can be achieved in >90% of the cases. Furthermore, this study will permit future conduct of a prospective randomized comparison of this technique with conventional LVRS.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Emphysema
  • Lung Volume Reduction Surgery
03

In context

Pulmonary Disease, Chronic Obstructive

5,520 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

This study's planned enrollment of 15 is below the median of 62 across 3,839 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

This is the only study on the registry with Rocco Bilancia as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age \< or equal 75 years
  2. Stable with less than or equal to 10mg prednisolone daily
  3. Nonsmoking for 3 months prior to screening and willing to not smoke during the study duration
  4. Willing and able to complete protocol required study follow-up assessments and procedures
  5. Fit for thoracoscopy under general anaesthesia (surgical and anaesthetic assessment)
  6. Recent (\< 18 months) endobronchial lung volume reduction (EBLVR) and lack of response defined by:

    1. Persistent symptomatic dyspnoea (mMRC >2) which in the patient's view is no better than baseline
    2. Absence of target lobar collapse with any residual aeration apparent on imaging
    3. Persistence of (6a) and (6b) following post procedure StratX CT analysis and revisional bronchoscopy.

Exclusion criteria

Exclusion criteria

  1. Fissure completeness \<90% on pre EBLVR StratX (i.e less than 10% of fissure to be divided)
  2. Chartis positive for collateral ventilation or not performed/not satisfactory at initial EBLVR
  3. Quantitative perfusion of target lobe >25% of total on SPECT assessment.
  4. Previous lung surgery or pleurodesis on the target side for LVR.
  5. bronchiectasis -greater than 4 tablespoons mucus per day.
  6. More than 3 exacerbation episodes in the last year.
  7. Evidence of hypercapnia (pCO2 >7KPa) - ABG to be performed on admission for index procedure
  8. Clear evidence of pulmonary hypertension (systolic pulmonary arterial pressure >45mmHg) or evidence or right ventricular dysfunction as determined by a recent echocardiogram (\<12mo)
  9. (LVEF) less than 40% as determined by a recent echocardiogram (\<12mo)
  10. Myocardial infarction within 6 months of screening.
  11. Unable to safely discontinue anticoagulants or activity inhibitors for 7 days.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Other
    Surgical Fissure Division

    Surgical Lung Fissure Division in patients who had endobronchial valves for severe emphysema and did not achieve lung volume reduction

    Procedure: Surgical Lung Fissure Division

Interventions

  • ProcedureSurgical Lung Fissure Division

    Thoracoscopic surgical division of interlobar fissure, in patients who did not achieve Lung Volume Reduction following Endobronchial Valve insertion. Standard thoracoscopic approach under general anaesthetic, as per individual surgeon preference or practice. Fissure identified and surgical division with mechanical stapler performed.

06

What researchers measure

Primary outcomes

  1. Number of patients recruited

    At least 15 patients recruited into the trial over 18 months

    Time frame: 18 months

  2. Number of patients where surgical division of inter-lobar fissure can be successfully completed

    Division of inter-lobar fissure can be completed in 90% of the patients enrolled

    Time frame: Through study completion (18 months)

  3. Number of patients who experience serious adverse events as a result of the intervention

    Number of patients who experience serious adverse events as a result of the intervention

    Time frame: Through study completion (18 months)

Secondary outcomes

  1. Target lobar collapse

    The number of patients achieving target lobar collapse

    Time frame: Through study completion (18 months)

  2. Costs

    The cumulative cost (in GBP) of hospital resources utilised (intraoperative consumables, theatre time, hospital stay, readmission costs)

    Time frame: Through study completion (18 months)

Other outcomes

  1. Number of patients screened

    Number of patients screened

    Time frame: Through study completion (18 months)

  2. Proportion of patients consenting to take part

    Proportion calculated with number of patients consented over patients screened

    Time frame: Through study completion (18 months)

  3. Number of patient with >90% data completed

    Number of patiens with \>90% data completed

    Time frame: Through study completion (18 months)

  4. Proportion of patients with complete follow up

    Number of patients with complete follow up post procedure (i.e. who completed visit 5) over patients who underwent the index procedure

    Time frame: Through study completion (18 months)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Magge A, Kent MS, Ospina-Delgado D, Swenson KE, Parikh MS, Zhang C, Gangadharan SP, Majid A. Robotic-assisted Fissure Completion for Lung Volume Reduction with Endobronchial Valves. Ann Am Thorac Soc. 2022 Dec;19(12):2087-2090. doi: 10.1513/AnnalsATS.202204-308CC. No abstract available. PubMed 36454166 ↗
  • Shafiq M, Polhemus E, Perkins R, Forth V, Marshall MB. Bilateral Bronchoscopic Lung Volume Reduction After Surgical Fissure Completion. Chest. 2022 Aug;162(2):e73-e75. doi: 10.1016/j.chest.2022.02.005. PubMed 35940665 ↗
  • Majid A, Kheir F, Alape D, Chee A, Parikh M, DeVore L, Agnew A, Gangadharan S. Combined Thoracoscopic Surgical Stapling and Endobronchial Valve Placement For Lung Volume Reduction With Incomplete Lobar Fissures: An Experimental Pilot Animal Study. J Bronchology Interv Pulmonol. 2020 Apr;27(2):128-134. doi: 10.1097/LBR.0000000000000617. PubMed 31436607 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

Of 1,094 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,181 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jul 2, 2026
StartEst.
Aug 2026
Primary completionEst.
Aug 2027
CompletionEst.
Jan 2028
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682168
Lead sponsor
Rocco Bilancia
Responsible party
Rocco Bilancia (Consultant Thoracic Surgeon, Golden Jubilee National Hospital) — Sponsor-investigator
First posted
Jul 2, 2026
Start date
Aug 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Jul 2, 2026

Study contacts

Rocco Bilancia, MD
Contact
rocco.bilancia@gjnh.scot.nhs.uk
0141 951 5660

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion